Clinical Trials Logo

Superficial Bladder Cancer clinical trials

View clinical trials related to Superficial Bladder Cancer.

Filter by:

NCT ID: NCT05084586 Recruiting - Bladder Cancer Clinical Trials

Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation

Start date: October 1, 2019
Phase: N/A
Study type: Interventional

In this study, the local and systemic side effects, tumor recurrens and progression rates of single or continuous epirubicin instillation during the early postoperative period were investigated in low and intermediate risk non-muscle-invasive bladder cancer.

NCT ID: NCT04752722 Recruiting - Clinical trials for Superficial Bladder Cancer

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Start date: April 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or inadequately treated.

NCT ID: NCT03379909 Recruiting - Bladder Cancer Clinical Trials

Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer

TROJAN
Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

A multi-center, open-label, phase II clinical study of metformin in up to evaluable 49 patients with low-grade NMIBC with the aim to determine the overall response to administration of oral metformin for 3 months in a index papillary NMIBC tumour.

NCT ID: NCT03121768 Recruiting - Bladder Cancer Clinical Trials

A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Start date: May 15, 2017
Phase: N/A
Study type: Observational

A prospective observational study to re-establish a new prognostic model for predicting the outcome in patients with non-muscle invasive bladder cancer (NMIBC) using the current recommendation regimen for intermediate and high risk groups and including all potential and highly prognostic factors.

NCT ID: NCT03091764 Completed - Clinical trials for Superficial Bladder Cancer

Evaluation of a Patient-Reported Symptom Index for NMIBC

Start date: July 1, 2016
Phase:
Study type: Observational [Patient Registry]

This project will develop and evaluate a patient-reported symptom index to assess the impact of treatment for non-muscle invasive bladder cancer on patient burden, toxicity, symptoms and side effects. The symptom index will provide a method for assessing treatments from the patient's perspective; help healthcare professionals make better informed treatment decisions, and provide a method to be able to effectively evaluate treatments for non-muscle invasive bladder cancer.

NCT ID: NCT02773849 Completed - Clinical trials for Superficial Bladder Cancer

ADSTILADRIN (=INSTILADRIN) in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

Start date: September 19, 2016
Phase: Phase 3
Study type: Interventional

Previous multi-dose Phase I and Phase II clinical studies have demonstrated that ADSTILADRIN is a safe and effective treatment for BCG-refractory and recurrent NMIBC. This Phase III study is designed to expand those observations using a high dose of ADSTILADRIN in patients that are "BCG Unresponsive" which refers to patients with high-grade NMIBC who are unlikely to benefit from and should not receive further intravesical BCG.

NCT ID: NCT02106572 Recruiting - Clinical trials for Superficial Bladder Cancer

Therapeutic Instillation of Mistletoe

TIM
Start date: April 2015
Phase: Phase 3
Study type: Interventional

The aim of this phase III study is to assess the efficacy of abnobaVISCUM® 900 compared with Mitomycin C (MMC) monotherapy in patients with superficial bladder carcinoma by evaluation of the time to tumor recurrence. Secondary objective is to evaluate the safety of abnobaVISCUM® 900, in particular, to compare the toxicity of the two treatments. Another secondary objective is the treatment efficacy as measured by calculated prognosis for recurrence and progression after 1 year, the tumor grading in case of a recurrence and by measurement of Quality of Life.

NCT ID: NCT02007005 Completed - Clinical trials for Superficial Bladder Cancer

Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer

Start date: January 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this phase Ib/IIa study is to investigate the maximum tolerable concentration of abnobaVISCUM® Fraxini for intravesical instillation in patients with superficial bladder cancer. Secondary objectives are the local and systemic tolerability, the influence on tumor remission and the influence on the one-year recurrence rate.

NCT ID: NCT01939756 Completed - Clinical trials for Lower Urinary Tract Symptoms

Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms

Baobab
Start date: January 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Baobab oil is often used in traditional medicine as antipyretic, antioxidant, anti-inflammatory, analgesic and antimicrobial. It also regenerates the epithelial tissue in a short time improving tone and elasticity. We want to evaluate the effects of intravesical Baobab oil in patients with BCG-induced lower urinary tract symptoms.

NCT ID: NCT01687244 Completed - Clinical trials for Superficial Bladder Cancer

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

Start date: September 2012
Phase: Phase 2
Study type: Interventional

This Phase 2 study is designed to assess the efficacy and safety of INSTILADRIN (rAd-IFN with Syn3) when given intravesically to patients with high grade non-muscle invasive bladder cancer who are refractory to or have relapsed from BCG therapy. The pharmacodynamics of INSTILADRIN will also be studied by measuring the interferon (IFNα2b) levels excreted in the urine. rAd-IFN is a non-replicating recombinant adenovirus type 5 (Ad5)-vector encoding the interferon alpha-2b (IFNα2b) gene. Syn 3 is clinical surfactant excipient which enhances the ability of the adenoviral vector to transfect cells in the bladder wall.